Johns Hopkins Doses Nasal Foralumab in MS Trial
Tiziana Life SciencesLife Sciences has initiated dosing at Johns Hopkins University, the third site in its Phase 2 trial...
Tiziana Life SciencesLife Sciences has initiated dosing at Johns Hopkins University, the third site in its Phase 2 trial...
Acumen Pharmaceuticals presented extended results from its plasma pTau217 assay used to screen participants in the Phase 2 ALTITUDE-AD...
CervoMed announced positive 16-week results from the extension phase of its Phase 2b RewinD-LB study of neflamapimod for dementia...
AC Immune announced positive interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein (a-syn) in early...
Connect Biopharma announced positive feedback from the FDA regarding its plan for two Phase 2 trials of rademikibart. The...
Microbot Medical announced that data from its ACCESS-PVI trial, evaluating the LIBERTY® Endovascular Robotic System for peripheral vascular interventions,...
Cerevance announced topline results from its Phase 2 ASCEND trial of solengepras, a non-dopaminergic drug candidate for early-stage, untreated...
Candel Therapeutics announced promising Phase 1b clinical trial results for CAN-2409 combined with nivolumab and standard care in newly...
Medera Inc. announced updated positive results from its Phase 1/2a clinical trial of SRD-002, a gene therapy for heart...
Advanced Medical Balloons (AMB) announced positive data from their HYDRA-PMCF study on hygh-tec®, a new polyurethane fecal management system...